Brookfield Asset Management Inc. Allogene Therapeutics, Inc. Transaction History
Brookfield Asset Management Inc.
- $14.2 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
178Shares Held
143MCall Options Held
37.5KPut Options Held
77.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$38.2 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$33.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$22.2 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$16.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$14.8 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $293M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...